Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat No.	product name
T9901	Adalimumab	Adalimumab (anti-TNF-alpha) is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.
T9902	Atezolizumab	Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of...
T9903	Avelumab	Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
T9904	Bevacizumab	Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
T9906	Ipilimumab	Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibit...
T9907	Nivolumab	Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human ce...
T9908	Pembrolizumab	Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
T9909	Pertuzumab	Pertuzumab (anti-HER2), a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2...
T9910	Rituximab	Rituximab (anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM.
T9911	Tocilizumab	Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor
T9912	Trastuzumab	Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER...
T9913	Ustekinumab	Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
T9914	Vedolizumab	Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
T9915	Eculizumab	Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5
T9916	Alirocumab	Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.
T9917	Denosumab	Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand
T9918	Daratumumab	Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells.
T9919	Alemtuzumab	Alemtuzumab is a humanized monoclonal antibody against CD52, an antigen found on the surface of normal and malignant lymphocytes.
T9920	Evolocumab	Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9).
T9921	Infliximab	Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis.
T9922	Matuzumab	Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR, frequently associated with the growth of blood vessels in...
T9923	Nimotuzumab	Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR).
T9924	Obinutuzumab/afutuzumab	Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
T9925	Ofatumumab	Ofatumumab is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation
T9926	Omalizumab	Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE)
T9927	Panitumumab	Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
T9928	Ranibizumab	Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A
T9929	Ramucirumab	Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors.
T9930	Secukinumab	Secukinumab is a fully humanized, monoclonal anti-IL-17A antibody, and the first in its class to be approved by the US Food and Drug Administration for the treat...